Therapeutic Response

PD-L1 >= 50% status confers therapeutic sensitivity to Atezolizumab in patients with Non-Small Cell Lung Cancer.

Statements

Source and description

Tecentriq (atezolizumab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to atezolizumab for the first-line treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (PD-L1 stained >= 50% of tumor cells [TC >= 50%] or PD-L1 stained tumor-infiltrating immune cells [IC] covering >= 10% of the tumor area [IC >= 10%] ), as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.